Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

Rhea-AI Summary

Design Therapeutics, a biotechnology company focused on treatments for degenerative genetic disorders, announced that CEO João Siffert will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference. This event is scheduled for June 9, 2021, at 1:20 p.m. ET. A live webcast will be available on the company's investor website and archived for 60 days. Design Therapeutics specializes in GeneTAC™ small molecules aimed at targeting disease-causing genes, with their lead program focusing on Friedreich ataxia.

News Market Reaction – DSGN

+1.32%

+1.32% Session move

In the trading session that priced this news, DSGN gained 1.32%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João Siffert, M.D., president and chief executive officer, will participate in a fireside chat during the Goldman Sachs 42^nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 1:20 p.m. ET.

The live webcast will be available in the investor section of the company's website at www.designtx.com. The webcast will be archived for 60 days following the presentation.

About Design Therapeutics
Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. Our GeneTAC molecules are designed to either turn on or turn off a specific disease-causing gene to address the underlying cause of disease. The company’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions. For more information, please visit designtx.com.

Contact:
Alicia Davis
THRUST Strategic Communications
(910) 620-3302
alicia@thrustsc.com

FAQ

When will João Siffert speak at the Goldman Sachs Global Healthcare Conference for DSGN?

João Siffert will speak on June 9, 2021, at 1:20 p.m. ET.

How can I watch the DSGN fireside chat?

The fireside chat can be viewed live on the investor section of Design Therapeutics' website.

What is the focus of Design Therapeutics?

Design Therapeutics focuses on developing therapies for degenerative genetic disorders using GeneTAC™ small molecules.

What is the lead program of Design Therapeutics?

The lead program targets Friedreich ataxia.

Where can I find more information about Design Therapeutics?

More information can be found on their website at designtx.com.